Search PubMed⌕ Search

Biomedical subjects

T A Ban

Publications and source records attributed to T A Ban.

At least 91 records · Page 5Linked to original sources
PubMed1980

Viloxazine: a review of the literature.

In animal pharmacological studies viloxazine has shown similarities to imipramine. The antidepressant effects of the substance were independently recognized in seven uncontrolled clinical trials and verified in 11 published standard controlled clinical studies in which viloxazine in the dosage range from 150- to 300-mg dosage was equal in overall therapeutic efficacy to imipramine and amitriptyline, but produced a lower incidence of side effects.

Clinical Trials as Topic↗
PubMed1980

Amoxapine: a review of literature.

Amoxapine, a new antidepressant, is a tricyclic debenzoxazepine compound, the demethylated metabolite of the neuroleptic loxapine. In animal pharmacological studies, amoxapine has shown striking similarities to imipramine. In contrast to the prototype antidepressant drug, however, amoxapine does not interact with serotonin. In 10 uncontrolled clinical trials amoxapine was shown to have antidepressant effects in the dosage range of 100-300 mg/day. This was verified in 10 published standard, and placebo and standard controlled clinical studies in which amoxapine was superior to placebo and equal in overall therapeutic efficacy to imipramine and amitriptyline. Side effects were similar to the reference drugs.

Amoxapine↗
PubMed1980

Viloxazine in the treatment of depressive neurosis: a placebo and standard (imipramine) controlled clinical study.

In a 4-week double-blind trial, 33 patients with depressive neurosis were randomly assigned to either viloxazine, imipramine or placebo. Statistically significant improvement was observed in all treatment groups. Imipramine exhibited significant improvement earlier in depressive symptoms, while viloxazine showed significant improvement earlier in anxious symptoms. The same frequency of treatment emergent symptoms occurred in the treatment groups. Premature termination as a consequence of adverse reactions was required in only 1 viloxazine and 1 placebo patient.

Adult↗
PubMed1980

A double-blind comparison of three dosages of flutroline (CP-36,584) in the treatment of schizophrenia.

Therapeutic and adverse effects of three dosages (1, 20 and 100 mg daily) of flutroline, a new gamma-carboline with a preclinical pharmacological profile similar to active neuroleptic agents, were compared in a double-blind clinical trial in 25 newly-admitted schizophrenic patients. Therapeutic effects and extrapyramidal signs were seen at the 20 and 100-mg daily dosages, but not at the 1-mg dosage. Serum prolactin levels were significantly elevated only at the 100-mg daily dosage.

Adolescent↗
PubMed1980

Viloxazine in the treatment of depressive neurosis: a controlled clinical study with doxepin and placebo.

In a four-week, double-blind, clinical trial thirty-one patients with depressive neurosis were treated with viloxazine, doxepin, or placebo. There were no differences among the three groups in therapeutic effects. Many depressed out-patients improve on placebo. Viloxazine hydrochloride is one of a series of compounds developed to explore the central nervous system activity of the aryloxypropanolamine type of beta-adreno-receptor antagonists. Initial clinical study support the hypothesis that viloxazine has antidepressant properties in man (Bayliss et al, 1974; Bereen, 1973; Pichot et al., 1975; Tsegos and Ekdawi, 1974).

Adult↗
PubMed1980

Possible lack of anticholinergic effects with mianserin: a pilot study.

Anticholinergic effects of mianserin, a new tetracyclic antidepressant, were studied in 5 depressed patients. Prior to and after 1 and 2 hours of the administration of 30 mg of mianserin salivary flow, pupilary response to light and palpebral fissure were measured. Analysis of data revealed a statistically significant increase in salivary flow and a statistically significant decrease in pupil diameter. There was no change in palpebral fissure size. Possible clinical implications of these findings will be discussed.

Adult↗
PubMed1980

Interaction of indomethacin and ibuprofen with lithium in manic patients under a steady-state lithium level.

The clinical effects of prostaglandin synthesis inhibitors were studied in lithium treated manic patients. While indomethacin increased plasma lithium concentration, the effect of ibuprofen was inconsistent. Adverse reactions included tremors unrelated to changes in plasma lithium levels; nausea and drowsiness in 1 ibuprofen treated patient possibly related to the slight increase in plasma lithium, and a syndrome consisting of running nose, malaise and generalized body aches in 1 indomethacin treated patient. Our findings are in support of an important interaction between prostaglandin synthesis inhibitors and especially indomethacin and lithium, which may result in an increase in adverse reactions.

Adult↗
PubMed1979

Adverse effects in maintenance treatment: practical and theoretical considerations.

1. Subsequent to the introduction of therapeutically effective psychotropic drugs, there has been a decrease in the resident population in mental hospitals. 2. Since maintenance therapy with neuroleptics and lithium may alleviate and/or prevent relapse in a considerable percentage of schizophrenic and manic depressive patients, there is a gradual increase of these patients in the community. 3. In this paper some of the adverse effects of long-term pharmacotherapy with psychotropic drugs will be presented, and possible negative effects of the increase in fertile marriages among community-based patients will be discussed.

Antidepressive Agents, Tricyclic↗
PubMed1979

Clobazam: uncontrolled and standard controlled clinical trials.

1 In an uncontrolled clinical trial, carried out in 11 psychiatric patients with the clinical diagnoses of anxiety neurosis and depressive neurosis, clobazam, a new benzodiazepine preparation, in the dosage range 10-60 mg daily produced statistically significant improvement in the total and both factor scores of the Hamilton Anxiety Scale (HAM-A). The lowest mean total HAM-A scores occurred with a mean clobazam dosage of 48 mg daily. 2 Results of the uncontrolled clinical trial were further substantiated in a standard-controlled clinical study in which no statistically significant difference between the therapeutic effectiveness of clobazam and diazepam could be revealed. The lowest mean total HAM-A scores occurred with a mean clobazam dosage of 49 mg daily. There was a lower incidence of adverse effects reported in patients receiving clobazam than in those taking the control drug (diazepam).

Adjustment Disorders↗
PubMed1978

A review of nicotinic acid, N-methylated indoleamines and schizophrenia.

The hypothesis that endogenously formed, N-methylated metabolites of indoleamines may play a role in the pathogenesis of schizophrenia was reviewed. Although N-methylated indoleamines can be produced in vivo and have significant psychotomimetic effects, there is little evidence for a specific increase in the methylation of indoleamines in schizophrenic patients. It was noted that even if the relationship between schizophrenia and N-methylated indoleamines had existed, nicotinic acid would not be an appropriate therapeutic agent.

Bufotenin↗
PubMed1978

Drug interactions in psychiatry.

Since maintenance therapy with neuroleptics, lithium and tricyclic antidepressants may have to continue over extended periods of time, drug interactions between these psychotherapeutic agents and non-psychotropic treatments have become of practical clinical significance. In this paper some of the more common or important drug interactions between psychotherapeutic and non-psychotherapeutic agents are discussed.

Antidepressive Agents, Tricyclic↗
PubMed1978

Butaclamol in the treatment of schizophrenia. A standard-controlled clinical trial.

A 16-week, standard-controlled, double-blind study was conducted to compare the efficacy of butaclamol with that of fluphenazine in the treatment of 24 newly admitted schizophrenic patients. Statistically significant improvement occurred in the entire population in the total scores of the BPRS and PAS; in the activation, anergia, thought disturbance and hostile/suspiciousness factor scores of the BPRS; and in the scores of 9 of the 12 factors of the PAS. There were no statistically significant differences between the scores of the two treatment groups on the total or factor scores of either scale during the course of the clinical trial. The most frequently occurring adverse effects in the butaclamol group were rigidity, akathisia and excitement/agitation. The most frequently occurring adverse effects in the fluphenazine group were insomnia, decreased motor activity and tremor. It is concluded that butaclamol exerts potent neuroleptic effects on schizophrenic patients.

Adult↗